Literature DB >> 8144898

Sublytic complement attack exposes C-reactive protein binding sites on cell membranes.

Y P Li1, C Mold, T W Du Clos.   

Abstract

C-reactive protein (CRP) is an acute phase serum protein synthesized by the liver. CRP has been localized to acute inflammatory sites and has been postulated to facilitate the removal of damaged cells. CRP binds to a number of ligands that may be present in inflammatory sites, and the extent to which individual ligands are involved in its binding to tissue sites is unknown. Complement activation is important in the tissue damage in many inflammatory conditions causing cell membrane damage and recruitment of inflammatory cells. This paper describes the binding of CRP to complement-damaged cell membranes. Raji cells activate the alternative complement pathway resulting in the deposition of C3b and membrane attack complexes (MAC) on the cell membrane. However, Raji cells are relatively resistant to killing by human complement. Treatment of Raji cells with human serum led to calcium-dependent phosphocholine-inhibitable CRP binding. CRP binding was eliminated by depletion of C3, C5, or C8 and reduced by depletion of C9 from serum. CRP binding preceded cell death and co-localized with MAC on cell membranes. CRP binding to complement-treated liposomes required phosphatidylcholine in addition to the MAC indicating that membrane phospholipids rather than the MAC proteins provide the binding sites for CRP. However, for both liposomes and Raji cells disruption of the lipid bilayer by complement attack was required for CRP binding to occur. These results support the hypothesis that CRP binding at sites of inflammation may be mediated by exposed phospholipids on damaged cell membranes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144898

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.

Authors:  C H Nielsen; H V Marquart; W M Prodinger; R G Leslie
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 2.  Complement in neuroprotection and neurodegeneration.

Authors:  Vijay Yanamadala; Robert M Friedlander
Journal:  Trends Mol Med       Date:  2010-01-28       Impact factor: 11.951

3.  Generation of C-reactive protein and complement components in atherosclerotic plaques.

Authors:  K Yasojima; C Schwab; E G McGeer; P L McGeer
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

4.  C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific.

Authors:  M P Stein; J C Edberg; R P Kimberly; E K Mangan; D Bharadwaj; C Mold; T W Du Clos
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 5.  C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity.

Authors:  Terry W Du Clos; Carolyn Mold
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

6.  Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration.

Authors:  K Lueck; S Wasmuth; J Williams; T R Hughes; B P Morgan; A Lommatzsch; J Greenwood; S E Moss; D Pauleikhoff
Journal:  Eye (Lond)       Date:  2011-05-20       Impact factor: 3.775

7.  Effects of C-reactive protein and pentosan polysulphate on human complement activation.

Authors:  Andis Klegeris; Edith A Singh; Patrick L McGeer
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

8.  Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis.

Authors:  Waliza Ansar; Sumi Mukhopadhyay; S K Hasan Habib; Shyamasree Basu; Bibhuti Saha; Asish Kumar Sen; C N Mandal; Chitra Mandal
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

Review 9.  C-reactive protein and the biology of disease.

Authors:  Waliza Ansar; Shyamasree Ghosh
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 10.  Physiological and Pathological Inflammation Induced by Antibodies and Pentraxins.

Authors:  Chiara Elisabeth Geyer; Lynn Mes; Melissa Newling; Jeroen den Dunnen; Willianne Hoepel
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.